A sequential doublet chemotherapy regimen in patients (pts) with advanced endometrial adenocarcinoma (EC) and gynecological mixed müllerian tumors (MMT). Maintaining activity with tolerability

5079 Background: Carboplatin (C), doxorubicin (D) and paclitaxel (P) have significant activity in advanced EC and MMT. Concurrent 3 drug regimens are associated with high activity but also significant toxicity. Sequential doublet regimens combining all three drugs may retain high levels of efficacy with acceptable levels of toxicity. Methods: Pts with Stage III-IV advanced EC or MMT received first line treatment, from 2001–2004, with 4 cycles of CD (C=AUC5, D=50mg/m2, d1q21) followed by 4 cycles of CP (C=AUC5, P=175mg/m2, d1q21). The primary endpoint was the % of pts completing all planned treatment. Results: 25 pts have completed treatment (19 EC, 6 MMT, median age 59) of whom 72% competed all 8 cycles of treatment (primary endpoint reached). 86% of all planned cycles of chemotherapy were delivered (172 out of a max possible of 200). Toxicity: 20% of cycles were delayed (85% by 1w, 12% by 2w and 3% by 3w), all for hematological toxicity (90% neutropenia, 10% thrombocytopenia). Non hematological toxicity ...